DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

ViroCell Biologics ("ViroCell" or the "Company"), a cell and gene therapy ("CGT") contract development and manufacturing organization ("CDMO") specializing in GMP viral vector manufacturing for ...

A new study in the journal Human Gene Therapy indicates that DNA impurities derived from plasmid and host cell DNA are ...

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

With a storied history in vaccine development, India's Bharat Biotech is shaking things up and answering the call of advanced ...

MeiraGTx's innovative gene therapies for ocular diseases & more are backed by strong clinical data and funding. Click here to find out why MGTX stock is a Buy.

and quite unexpected step of the pharma giant into the adeno-associated virus (AAV) gene therapy, vector discovery and product development. AAV vectors are responsible for transporting genes to ...

Scientists from Juntendo University and The University of Tokyo have created an adeno-associated virus (AAV)-based genome ...

Part of the limitations, which have added friction to the commercialisation of therapies targeting neuromuscular disorders, are tied to the nature of the vectors used to deliver these treatments.

Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death ...

Base editing corrected a mutation that causes macular degeneration, highlighting the potential of gene therapy to treat ...